Drugs / Reboxetine
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00886886 | Apr → Dec 2009 | mood disorder, substance-related disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT00409201 | Mar → Nov 2006 | schizophrenia | Abarbanel Mental Health Center | Unknown | No outcome recorded |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT05978505 | Aug 2023 → Jul 2025 overdue | obstructive sleep apnea syndrome | Flinders University | Recruiting | No outcome recorded |
| Phase 2 | NCT05133804 | Jun 2022 → Jul 2025 overdue | post-traumatic stress disorder | University of Haifa | Recruiting | No outcome recorded |
| Phase 2 | NCT04449133 | Jul → Oct 2020 | obstructive sleep apnea syndrome | Istituto Auxologico Italiano | Completed | Met primary |
| Phase 2 | NCT00138749 | Nov 2004 → Aug 2006 | female stress incontinence | Pfizer | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT04394143 | Oct 2020 → Jul 2021 | obstructive sleep apnea syndrome | Raphael Heinzer | Completed | Missed primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT05880342 | May 2023 → Dec 2025 overdue | — | Vrije Universiteit Brussel | Recruiting | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT00853866 | Jan → Nov 2009 | stroke disorder | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| Phase 4 | NCT00426946 | Jan 2005 → ? | depressive disorder | Geha Mental Health Center | Unknown | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT04384562 | Dec 2020 → Dec 2021 | — | University of Zurich | Completed | No outcome recorded |
| — | NCT04371146 | Jul 2019 → Feb 2020 | — | University of Zurich | Completed | No outcome recorded |
| — | NCT03957174 | Jun 2019 → Jun 2020 | — | University of Oxford | Completed | No outcome recorded |
| — | NCT00421369 | Sep 2007 → Aug 2011 | major depressive disorder | Hadassah Medical Organization | Completed | No outcome recorded |
| — | NCT00993876 | Aug 2005 → Aug 2008 | — | Zentrum für Integrative Psychiatrie | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT04097288 Comparator | Sep 2019 → Feb 2020 | female stress incontinence | University Hospital Bispebjerg and Frederiksberg | Completed | No outcome recorded |
| Phase 3 | NCT02179268 Comparator | Mar 2012 → Apr 2014 | osteoporosis | Guiyang Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01300364 Comparator | Nov 2008 → Dec 2011 | schizophrenia | Fundació Sant Joan de Déu | Unknown | No outcome recorded |
| Phase 4 | NCT00209807 Comparator | Sep 2005 → Jun 2009 | major depressive disorder, pain agnosia | Hospital Universitari Vall d'Hebron Research Institute | Unknown | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | reboxetine | “An 8-Week, Multi-Centre,Randomised Double-Blind, Placebo Controlled, Parallel Group Study To Evaluate The Efficacy,Toleration And Safety Of (+)- [S,S]- Reboxetine In The...” NCT00138749 ↗19“Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial.” PMID 36861433 ↗ Jul 2023 “comparing 4 mg reboxetine plus 5 mg oxybutynin (Reb-Oxy) vs placebo in patients with OSA.” PMID 34543665 ↗ Sep 2021 |
| Known as | REB | “Participants ingested methylphenidate (MPH; 20 mg; primarily enhancing DA signaling), reboxetine (REB; 8 mg; selectively enhancing NA signaling), or placebo (10 mg lactose)...” PMID 41601207 ↗ Feb 2026 |
| Action | Inhibit | “Reboxetine, a highly selective norepinephrine reuptake inhibitor” NCT00426946 ↗ |
| Route | Oral | “Participants in the noradrenaline reuptake inhibitor group will be asked to take one pill containing 8 mg reboxetine 1.5 hours before performing the tasks.” NCT04371146 ↗ |